Table 2 Response categories across the three arms

From: A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer

Arm

RCB 0 (pCR)

RCB 1

RCB 2

RCB 3

A

3 (42.8%)

1 (14.2%)

1 (14.2%)

1 (14.2%)

B

4 (66.6%)

1 (16.7%)

1 (16.7%)

0

C

13 (72.2%)

3 (16.7%)

2 (11.1%)

0

Back to article page